Biomagnetic methods: Technologies applied to pharmaceutical research

Pharmaceutical Research

Volumn 28, Issue 3, 2011, Pages 438-455

  Corá, Luciana A ^a,d   Américo, Madileine F ^b,c   Oliveira, Ricardo B ^d   Serra, Cristina H R ^d   Baffa, Oswaldo ^d   Evangelista, Raul C ^c   Oliveira, Giselle F ^c   Miranda, José Ricardo Aruda ^c  

^a UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

drug delivery; gastrointestinal physiology; imaging; pharmacokinetic; solid dosage forms

Indexed keywords

AMOXICILLIN; BILE SALT; CLAVULANIC ACID; DICLOFENAC; ENZYME; TRIAMCINOLONE;

AC BIOSUSCEPTOMETRY; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ANISOTROPIC MAGNETORESISTIVE; BIOMAGNETIC METHOD; BIOSENSOR; CELL MEMBRANE TRANSPORT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; ENTERIC COATED TABLET; FOOD; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; GASTROINTESTINAL TRANSIT; HUMAN; MAGNETOTHERAPY; PHYSICAL CHEMISTRY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROCESS TECHNOLOGY; REVIEW; SIGNAL DETECTION; STOMACH EMPTYING; STOMACH JUICE; STOMACH PH; SUPERCONDUCTING QUANTUM INTERFERENCE DEVICE;

ANIMALS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; MAGNETICS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79952485717     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0285-5     Document Type: Review

References (114)

1. McConnel EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008;364 (2):213-26.
2. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11-22. (Pubitemid 28080861)
3. Wilding IR, Coupe AJ, Davis SS. The role of γ-scintigraphy in oral drug delivery. Adv Drug Deliv Rev. 2001;46:103-24.
4. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an envolving technology in pharmaceutical formulation development: part 1. Pharm Sci Tech. 1998;1(3):100-7. (Pubitemid 28326331)
5. Digenis GA, Sandefer EP, Page RC, Doll WJ. Gamma scintigraphy: an envolving technology in pharmaceutical formulation development: part 2. Pharm Sci Tech. 1998;1(4):160-5. (Pubitemid 28343471)
6. Jain S, Dani P, Sharma RK. Pharmacoscintigraphy: a blazing trail for the evaluation of new drugs and delivery systems. Crit Rev Ther Drug Carrier Syst. 2009;26(4):373-426.
7. Hodges LA, Connolly SM, Band J, O'Mahony B, Ugurlu T, Turkoglu M, et al. Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers. Int J Pharm. 2009;370:144-50.
8. Weitschies W, Kosch O, Mönnikes H, Trahms L. Magnetic marker monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked dosage forms. Adv Drug Deliv Rev. 2005;57(8):1210-22. (Pubitemid 40797575)
9. Corá LA, Romeiro FG, Stelzer M, Américo MF, Oliveira RB, Baffa O, et al. AC Biosusceptometry in the study of drug delivery. Adv Drug Deliv Rev. 2005;57(8):1223-41. (Pubitemid 40797576)
10. Andrä W, Danan H, Kirmsse W, Kramer HH, Saupe P, Schmieg R, et al. A novel method for real-time magnetic marker monitoring in the gastrointestinal tract. Phys Med Biol. 2000;45:3081-93.
11. Corá LA, Américo MF, Romeiro FG, Oliveira RB, Miranda JRA. Pharmaceutical applications of AC Biosusceptometry. Eur J Pharm Biopharm. 2010;74:67-77.
12. Weitschies W, Blume H, Mönnikes H. Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. Eur J Pharm Biopharm. 2010;74:93-101.
13. Corá LA, Américo MF, Oliveira RB, Baffa O, Moraes R, Romeiro FG, et al. Disintegration of magnetic tablets in human stomach evaluated by alternate current Biosusceptometry. Eur J Pharm Biopharm. 2003;56:413-20. (Pubitemid 37346516)
14. Corá LA, Andreis U, Romeiro FG, Américo MF, Oliveira RB, Baffa O, et al. Magnetic images of the disintegration process of tablets in the human stomach by AC Biosusceptometry. Phys Med Biol. 2005;50:5523-34. (Pubitemid 41750438)
15. Corá LA, Romeiro FG, Paixão FC, Américo MF, Oliveira RB, Baffa O, et al. Enteric coated magnetic HPMC capsules evaluated in human gastrointestinal tract by AC Biosusceptometry. Pharm Res. 2006;23:1809-16. (Pubitemid 44200544)
16. Corá LA, Fonseca PR, Américo MF, Oliveira RB, Baffa O, Miranda JRA. Influence of compression forces on tablets disintegration by AC Biosusceptometry. Eur J Pharm Biopharm. 2008;69:372-9.
17. Miranda JRA, Corá LA, Américo MF, Romeiro FG. AC Biosusceptometry technique to evaluate the gastrointestinal transit of pellets under influence of prandial state. J Pharm Sci. 2010;99:317-24.
18. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release. 2005;108:375-85. (Pubitemid 41608669)
19. Weitschies W, Friedrich C, Wedemeyer RS, Schmidtmann M, Kosch O, Kinzig M, et al. Bioavailability of amoxicilin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm. 2008;70:641-8.
20. Bergstrand M, Söderlind E, Weitschies W, Karlsson MO. Mechanistic modeling of a magnetic marker monitoring study, linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Clin Pharmacol Ther. 2009;86(1):77-83.
21. Custodio J, Wu CY, Benet L. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60:717-33.
22. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50(1):3-12. (Pubitemid 30326685)
23. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
24. Silva MF, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CHR. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy brazilian volunteers. Clin Ther. 2010;32:758-65.
25. Armando YP, Schramm SG, Silva MF, Kano EK, Koono EEM, Porta V, et al. Bioequivalence assay between orally desintegrating and conventional tablet formulations in healthy volunteers. Int J Pharm. 2009;21:149-53.
26. Serra CHR, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clin Ther. 2008;30(5):902-8. (Pubitemid 351799868)
27. Jackson AJ. Generics and bioequivalence. Boca Raton: CRC; 1994.
28. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailaility is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther. 1996;60(6):601-7. (Pubitemid 27025907)
29. Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273-85. (Pubitemid 40326200)
30. Shen Q, Li X, Yuan D, Jia W. Enhanced oral bioavailability of daidzein by self-microemulsifying drug delivery system. Chem Pharm Bull. 2010;58(5):639-43.
31. Chen ML. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Deliv Rev. 2008;60:768-77.
32. Karalis V, Macheras P, Peer A, Shah V. Bioavailability and bioequivalence: focus on physiological factors and variability. Pharm Res. 2008;25(8):1956-62.
33. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42:620-43. (Pubitemid 34547446)
34. Shargel L, Yu ABC, Pong SW. Applied biopharmaceutics & pharmacokinetics. New York: MacGraw-Hill; 2005.
35. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos. 1995;16:351-80.
36. Wilson CG. Gastrointestinal transit and drug absorption. In: Dressman JB, Lennernäs H, editors. Oral drug absorption, prediction and assessment. New York: Dekker; 2000. p. 1-10.
37. Hillgren KM, Kato A, Borchardt RT. In vitro systems for studying intestinal drug absorption. Med Res Rev. 1995;15(2):83-109.
38. Lennernäs H. Human intestinal permeability. J Pharm Sci. 1997;87(4):403-10. (Pubitemid 28175799)
39. Fangerholm U, Johansson M, Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1996;13:1336-42. (Pubitemid 26344978)
40. Fangerholm U, Lindahl A, Lennernäs H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol. 2007;49:687-90.
41. Salana NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Del Rev. 2006;58:15-28.
42. Fangerholm U, Nilsson D, Knutson L, Lennernäs H. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. Acta Physiol Scand. 1999;165:315-24. (Pubitemid 29123551)
43. Tannergren C, Bergendal A, Lennernäs H, Abrahamsson B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Molecular Pharm. 2009;6:60-73.
44. Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Rev. 2001;48:173-93. (Pubitemid 32434402)
45. Apparaju SK, Nallani SC. Pharmacokinetics: basics of drug absorption from a biopharmaceutical perspective. In: Chilukuri DM, Sunkara G, Young D, editors. Pharmaceutical product development: in vitro-in vivo correlation. New York: Informa Healthcare; 2007. p. 29-46.
46. Grassi M, Grassi G, Lapasin R, Colombo I. Understanding drug release and absorption mechanisms: a physical and mathematical approach. Boca Raton: CRC; 2007.
47. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23(8):1675-86. (Pubitemid 44200529)
48. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99(6):2739-49.
49. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006;109:137-61. (Pubitemid 41740818)
50. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release. 1999;62:25-31. (Pubitemid 29486478)
51. Legen I, Salobir M, Kerc J. Comparison of different intestinal epithelia as models for absorption enhancement studies. Int J Pharm. 2005;291:183-8. (Pubitemid 40222010)
52. Gonzales-Mariscal L, Nava P. Tight junctions, from tight intercellular seals to sophisticated protein complexes involved in drug delivery, pathogen interaction and cell proliferation. Adv Drug Deliv Rev. 2005;57:811-4. (Pubitemid 40488105)
53. Junginger HE, Verhoef JC. Macromolecules as safe penetration enhancers for hydrophilic drugs action? Pharm Sci Technol Today. 1998;1:370-6.
54. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull. 2002;25:149-64. (Pubitemid 39592096)
55. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996;136:117-39. (Pubitemid 26199405)
56. Singh BH. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37:213-55.
57. Johnson LR. Gastrointestinal physiology. Philadelphia: Mosby, Elsevier; 2007.
58. Quigley EMM. Gastric and small intestinal motility in health and disease. Gastroenterol Clin North Am. 1996;25(1):113-45. (Pubitemid 26093559)
59. Rao SSC, Singh S, Mudipalli R. Day-to-day reproducibility of prolonged ambulatory colonic manometry in healthy subjects. Neurogastroenterol Motil. 2010;22:640-8.
60. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology. 2006;131:640-58. (Pubitemid 44142441)
61. Dressman JB, Vertzoni M, Goumas K. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev. 2007;59:591-602. (Pubitemid 47287780)
62. Kortejärvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J PharmSci. 2007;30:155-66. (Pubitemid 46157177)
63. Hellströn PM, Grybäck P, Jacobsson H. The physiology of gastric emptying. Best Pract Res Clin Anaesth. 2006;20:397-407. (Pubitemid 44317679)
64. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia: Lea & Febiger; 1991.
65. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27:886-92. (Pubitemid 16044258)
66. Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci. 1993;82:857-72. (Pubitemid 23317246)
67. Kuo B, McCallum RW, Koch KL, Sitrin MD, Wo JM, Chey WD, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186-96. (Pubitemid 350256610)
68. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6:501-8. (Pubitemid 44340666)
69. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249-57. (Pubitemid 40222218)
70. Chawla G, Gupta P, Koradia V, Bansal AK. A means to address regional variability in intestinal drug absorption. Pharm Technol. 2003;27:50-68. (Pubitemid 37101890)
71. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8:360-4.
72. Charman WN, Porter CJH, Mithani S, Dressman J. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86 (3):269-82. (Pubitemid 27113759)
73. Patel M, Shah T, Amin A. Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carr Syst. 2007;24(2):147-202. (Pubitemid 47324847)
74. Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S. Colonic drug delivery: an updated review. AAPS Pharm Sci. 2003;5:1-25.
75. Russell TL, Berardi RR, Barnett JL, Dermentzoglou LC, Jarvenpaa KM, Schmaltz SP, et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, north american men and women. Pharm Res. 1993;10(2):187-96. (Pubitemid 23041729)
76. Ward N. The impact of intestinal failure on oral drug absorption: a review. J Gastrointest Surg. 2010;14:1045-51.
77. Burton PS, Goodwin JT, Vidmar TJ, Amore BM. Predicting drug absorption: how nature made it a difficult problem. J Pharmacol Exp Ther. 2002;303(3):889-95. (Pubitemid 35424368)
78. Gai MN, Isla A, Andonaeugui MT, Thielemann AM, Seitz C. Evaluation of the effect of three different diets on the bioavailability of two sustained release theophylline matrix tablets. Int J Clin Pharm Ther. 1997;35:565-71. (Pubitemid 28010385)
79. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6(6):1631-43.
80. Varma MVS, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, et al. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab. 2004;5(5):375-88. (Pubitemid 39276602)
81. Varum FJO, Merchant HA, Basit AW. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption. Int J Pharm. 2010;395:26-36.
82. Williamson SJ, Kaufman L. Biomagnetism. J Magn Magn Mater. 1981;22:129-201.
83. Sternickel K, Braginski AI. Biomagnetism using SQUIDs: status and perspectives. Supercond Sci Technol. 2006;19:160-71.
84. Kwiatkowski W, Tumanski S. The permalloy magnetoresistive sensors: properties and applications. J Phys E Sci Instrum. 1986;19:502-15. (Pubitemid 16605198)
85. Baffa O, Oliveira RB, Miranda JRA, Troncon LEA. Analysis and development of an AC Biosusceptometer for orocaecal transit time measurements. Med Biol Eng Comput. 1995;33:353-7.
86. Pizzella V, Della Penna S, Del Gratta C, Romani GL. SQUID systems for biomagnetic imaging. Supercond Sci Technol. 2001;14:79-114.
87. Kleiner R, Koelle D, Ludwig F, Clarke J. Superconducting quantum interference devices: state of the art and applications. Proc IEEE. 2004;92(10):1534-48. (Pubitemid 40902546)
88. Swithenby SJ. SQUIDS and their applications in the measurement of weak magnetic fields. J Phys E Sci Instrum. 1980;13:801-13.
89. Mapps DJ. Magnetoresistive sensors. Sens Actuator. 1997;59:9-19. (Pubitemid 127388895)
90. Weitschies W, Grützmann R, Hartmann V, Breitkreutz J. Investigation of the disintegration of magnetically marked tablets. Eur J Pharm Biopharm. 2001;52:221-6. (Pubitemid 32755901)
91. Andrä W, Danan H, Eitner K, Hocke M, Kramer HH, Parusel H, et al. A novel magnetic method for examination of bowel motility. Med Phys. 2005;32(9):2942-4. (Pubitemid 41384091)
92. Américo MF, Oliveira RB, Corá LA, Marques RG, Romeiro FG, Andreis U, et al. The ACB technique: a biomagnetic tool for monitoring gastrointestinal contraction directly from smooth muscle in dogs. Physiol Meas. 2010;31:159-69.
93. Américo MF, Miranda JR, Corá LA, Romeiro FG. Electrical and mechanical effects of hyoscine butylbromide on the human stomach: a non-invasive approach. Physiol Meas. 2009;30:363-70.
94. Bahadur D, Giri J. Biomaterials and magnetism. Sadhana. 2003;28:639-56.
95. Kushchevskaya NF. Use of ferromagnetic particles in medicine. Powder Metall Met Ceram. 1997;36:668-72.
96. Goodman K, Hodges LA, Band J, Stevens HNE, Weitschies W, Wilson CG. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy. Eur J Pharm Biopharm. 2010;74:84-92.
97. Weitschies W, Karaus M, Cordini D, Trahms L, Breitkreutz J, Semmler W. Magnetic marker monitoring of disintegrating capsules. Eur J Pharm Sci. 2001;13:411-6. (Pubitemid 32611599)
98. Corá LA, Romeiro FG, Americo MF, Oliveira RB, Baffa O, Stelzer M, et al. Gastrointestinal transit and disintegration of enteric coated magnetic tablets assessed by AC Biosusceptometry. Eur J Pharm Sci. 2006;27:1-8. (Pubitemid 41728249)
99. Oliveira GF, Ferrari PC, Carvalho LQ, Evangelista RC. Chitosan-pectin multiparticulate systems associated with enteric polymers for colonic drug delivery. Carb Pol. 2010. in press.
100. Osmanoglou E, Van der Voort IR, Fach K, Kosch O, Hartmann V, Strenzke A, et al. Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. Neurogastroenterol Motil. 2004;16:547-56. (Pubitemid 39472188)
101. Li CH, Martini LG, Ford JL, Roberts M. The use of hypromellose in oral drug delivery. J Pharm Pharmacol. 2005;57:533-46. (Pubitemid 40562392)
102. Levina M, Rajabi-Siahboomi AR. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci. 2004;93:2746-54. (Pubitemid 39506625)
103. Bodmeier R. Tableting of coated pellets. Eur J Pharm Biopharm. 1997;43:1-8. (Pubitemid 28298804)
104. Gandhi R, Chaman LK, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today. 1999;2:160-70. (Pubitemid 29195749)
105. Krämer J, Blume H. Biopharmaceutical aspects of multiparticulates. In: Multiparticle oral drug delivery. New York: Marcel Dekker. 1994.
106. Asghar LFA, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci. 2006;9:327-38. (Pubitemid 46614339)
107. Hebbard GS, Sun WM, Bochner F, Horowitz M. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin Pharmacokinet. 1995;28:41-66.
108. Groop LC, DeFronzo RA, Luzi L, Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet. 1989;334:129-30. (Pubitemid 19180576)
109. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med. 2002;19:177-94. (Pubitemid 34429648)
110. Dieterlen P, Cassereau H, Lestradet H. Permanent malabsorption of rifampin in a diabetic with celiac disease. Arch Fr Pediatr. 1986;43:421-2.
111. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med. 1993;329:1122-3.
112. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Jansen J. Loperamide, survey of studies on mechanism of its anti-diarrhoeal activity. Digest Dis Sci. 1993;38:977-95. (Pubitemid 23175117)
113. Barone JA. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother. 1999;33:429-40. (Pubitemid 29215810)
114. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19:379-90. (Pubitemid 38297106)